IMUX
NASDAQ
$15
Immunic Inc (IMUX)
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a line of selective oral immunology therapies for the treatment of chronic autoimmune and inflammatory diseases. The company is headquartered in New York, New York.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $44.67 (+197.80%)
Market Cap
$206M
Free Cash Flow Yield
-39.60%
Beta (5Y)
1.28
Price Chart
Valuation
Market Cap$206M
P/B1.32
Profitability
EBITDA-$109M
EPS-$9.31
Financial Health
Free Cash Flow Yield-39.60%
Growth & Risk
EPS 5Y CAGR-24.37%
FCF 5Y CAGR+12.48%
Beta (5Y)1.28
Sharpe Ratio0.94